Regeneron Pharmaceuticals, Inc.

Regeneran Pharmaceuticals, Inc.

Erica Pyles

Nisha Palackal

Thomas Daly

Andrew Tustian

Ankit Vartak

Shunhai Wang

Ning Li

Nina Liu

Michael Rosconi

Andrew J Murphy

Eric L Smith

Samuel H Davis

Tong Zhang

Supriya Patel

Chia-Yang Lin

Matthew Franklin

Amardeep Singh Bhupender Bhalla

Jaimie Mastrogiacomo

Hunter Chen

Shawn Lawrence

Meghan Casey

Shawn M Lawrence

Amy S Johnson

Meghan E Casey

Jaimie Grapel

Gangadhar Dhulipala

Kun Lu

Chiayang Lin

Methods for characterizing protein complexes formed between protein drug products and soluble ligands are provided herein. The disclosed methods can determine the size, heterogeneity, and conformation of protein complexes.

Methods for characterizing protein complexes

Antigen binding molecules (ABMs) comprising Fab domains in non-native configurations, ABM conjugates comprising the ABMs and cytotoxic or cytostatic agents, pharmaceutical compositions containing the ABMs and ABM conjugates, methods of using the ABMs, ABM conjugates and pharmaceutical compositions for treating cancer, nucleic acids encoding the ABMs, cells engineered to express the ABMs, and methods of producing ABMs.

Antigen binding molecule formats

The present disclosure pertains to compositions comprising aflibercept and methods for producing such compositions in chemically defined media and using chromatography to reduce certain aflibercept variants.

Anti-VEGF protein compositions and methods for producing the same

The present disclosure pertains to compositions comprising anti-VEGF proteins.

The present disclosure pertains to methods for producing aflibercept from a host cell cultured in a chemically defined medium (CDM) including purification of aflibercept, wherein aflibercept following purification includes aflibercept variants that have at least one oxidized amino acid residue selected from the group consisting of tryptophan, histidine and a combination thereof.

Methods for detecting and/or discriminating between variants of an antibody contaminating protein or multiple antibodies in a sample by a physical parameter, in which the method includes: separating protein components of a sample by molecular weight or charge in one or more capillaries using capillary electrophoresis; immobilizing the protein components of the sample within the one or more capillaries; contacting the protein components within the one or more capillaries with one or more primary antibodies that specifically bind to the antibody, the contaminating protein or multiple antibodies in the sample, thereby detecting and/or discriminating between variants in the sample.

Ce-western applications for antibody development

The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions.

Growing community of inventors

New City, NY, United States of America

Erica Pyles